Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The pathologist's view point. Part I--indolent lymphomas.

S A Pileri¹, S Ascani, E Sabattini

¹Service of Pathologic Anatomy and Haematopathology, Institute Hematology and Oncology L. & A. Seràgnoli, Bologna University, Policlinico S. Orsola, Italy. pileri@almadns.unibo.it

|December 13, 2000

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

FLT3-targeted therapy restores GATA1 pathway function in NPM1/FLT3-ITD mutated acute myeloid leukaemia.

EJHaem·2023

Same author

EBV persistence in gastric cancer cases conventionally classified as EBER-ISH negative.

Infectious agents and cancer·2022

Same author

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.

ESMO open·2021

Same author

Correction to: A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit.

Virchows Archiv : an international journal of pathology·2019

Same author

A practical algorithmic approach to mature aggressive B cell lymphoma diagnosis in the double/triple hit era: selecting cases, matching clinical benefit : A position paper from the Italian Group of Haematopathology (G.I.E.).

Virchows Archiv : an international journal of pathology·2019

Same author

Primary cutaneous peripheral T-cell lymphoma not otherwise specified a rare and aggressive lymphoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018

The REAL/WHO classification aids understanding and treating malignant lymphomas. This study focuses on indolent B-cell lymphomas, improving pathologist-clinician communication for better patient care.

Area of Science:

Hematology
Oncology
Pathology

Background:

The REAL/WHO classification provides a framework for understanding and treating malignant lymphomas.
Focus on B-cell lymphomas with indolent behavior is crucial for clinical management.
Effective communication between pathologists and clinicians is essential for optimal patient outcomes.

Purpose of the Study:

To elucidate key features of indolent B-cell lymphomas.
To facilitate better understanding and treatment strategies for malignant lymphomas.
To enhance collaboration between pathologists and clinicians.

Main Methods:

Analysis of the literature and extensive personal experience with over 20,000 lymphoid tumors spanning 20 years.
Review of representative contributions for each lymphoma entity.

Related Experiment Videos

Application of novel markers to selected data.

Main Results:

Identification and discussion of diagnostic guidelines for indolent B-cell lymphomas.
Highlighting areas for future clinico-pathologic studies.
Presentation of data from novel marker applications.

Conclusions:

Current knowledge and classification of malignant lymphomas enable tailored therapy development.
Improved understanding of indolent B-cell lymphomas supports personalized treatment approaches.
The classification system facilitates advancements in lymphoma treatment strategies.